Quốc gia: Úc
Ngôn ngữ: Tiếng Anh
Nguồn: Department of Health (Therapeutic Goods Administration)
clopidogrel hydrogen sulfate
Sanofi-Aventis Australia Pty Ltd
clopidogrel hydrogen sulfate
CLOPIDOGREL SANOFI 1 CLOPIDOGREL SANOFI* TABLETS _Clopidogrel _ _ _ _ _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Clopidogrel Sanofi tablets. It does not contain all the available information. Some of the information it contains may not apply to you. It does not take the place of talking to your doctor or pharmacist. All medicines have benefits and risks. In deciding to give you Clopidogrel Sanofi, your doctor has weighed the risks of you taking Clopidogrel Sanofi against the expected benefits it will have for you. Always follow the instructions that your doctor and pharmacist give you about Clopidogrel Sanofi tablets. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. PLEASE READ THIS LEAFLET CAREFULLY BEFORE YOU START TAKING CLOPIDOGREL SANOFI. YOU MAY WISH TO KEEP IT TO READ AGAIN. WHAT IS CLOPIDOGREL SANOFI USED FOR CLOPIDOGREL SANOFI CONTAINS THE MEDICINE CLOPIDOGREL. CLOPIDOGREL SANOFI BELONGS TO A GROUP OF MEDICINES CALLED ANTI-PLATELET MEDICINES. Platelets are very small blood cells which clump together during blood clotting. By preventing this clumping, anti-platelet medicines reduce the chances of blood clots forming (a process called thrombosis). Clopidogrel Sanofi is used to prevent blood clots forming in hardened blood vessels (a process known as atherothrombosis) which can lead to events such as stroke, heart attack or death. You may have been prescribed Clopidogrel Sanofi to help prevent blood clots forming and to reduce the risk of stroke, heart attack and death because: • YOU HAVE PREVIOUSLY SUFFERED A HEART ATTACK, STROKE OR HAVE A CONDITION KNOWN AS PERIPHERAL ARTERIAL DISEASE (LEG PAIN ON WALKING OR AT REST). • YOU HAVE SUFFERED ACUTE CORONARY SYNDROME (EITHER A SEVERE TYPE OF CHEST PAIN CALLED UNSTABLE ANGINA, OR A HEART ATTACK). IN THIS CASE YOU MAY ALSO BE PRESCRIBED ASPIRIN. Your doctor may have prescribed this medicine for another use. If you want more information, ask your doctor. Clopidogre Đọc toàn bộ tài liệu
PRODUCT INFORMATION CLOPIDOGREL SANOFI -Clopidogrel hydrogen sulfate clopidogrel-sanofi-ccdsv23-piv12-13sep17 Page 1 PRODUCT INFORMATION CLOPIDOGREL SANOFI NAME OF THE MEDICINE AUSTRALIAN APPROVED NAME Clopidogrel hydrogen sulfate CHEMICAL STRUCTURE Clopidogrel hydrogen sulfate has the following chemical structure: C O O S N H Cl ,H 2 SO 4 CH 3 Molecular Formula: C 16 H 16 ClNO 2 S.H 2 SO 4 Molecular Weight: 419.9. Chemical Name: methyl (+)-(S)- α -(2-chlorophenyl)-6,7-dihydrothieno[3,2-c] pyridine-5(4H)- acetate sulfate (1:1) CAS REGISTRY NUMBER 120202-66-6 (Clopidogrel hydrogen sulfate), 113 665-84-2 (Clopidogrel base) DESCRIPTION Clopidogrel hydrogen sulfate is a white to off-white powder. It is practically insoluble in water at neutral pH but freely soluble at pH 1. It is freely soluble in methanol, sparingly soluble in methylene chloride and is practically insoluble in ethyl ether. It has a specific optical rotation of about + 56 ° . Each tablet contains mannitol, macrogol 6000, microcrystalline cellulose, hydrogenated castor oil, hyprolose. The coating contains lactose, hypromellose, titanium dioxide, glycerol triacetate, iron oxide red and carnauba wax. PRODUCT INFORMATION CLOPIDOGREL SANOFI -Clopidogrel hydrogen sulfate clopidogrel-sanofi-ccdsv23-piv12-13sep17 Page 2 PHARMACOLOGY PHARMACODYNAMICS Clopidogrel is a specific and potent inhibitor of platelet aggregation. Platelets have an established role in the pathophysiology of atherosclerotic disease and thrombotic events. Long term use of anti-platelet drugs has shown consistent benefit in the prevention of ischaemic stroke, myocardial infarction and vascular death in patients at increased risk of such outcomes, including those with established atherosclerosis or a history of atherothrombosis MECHANISM OF ACTION The active metabolite, a thiol derivative, is formed by oxidation of clopidogrel to 2- oxoclopidogrel and subsequent hydrolysis. The active metabolite of clopidogrel selectively inhibits the binding of ADP to its platelet P2Y 12 .receptor a Đọc toàn bộ tài liệu